Ashkan Shoamanesh

17 Ways to Cut Your Risk of Stroke, Dementia and Depression All at Once A new study identified overlapping factors that affect your odds of developing these brain diseases late in life.

Proudly sharing our publication featured in NY Times: 17 Ways to Cut Your Risk of Stroke, Dementia and Depression All at Once www.nytimes.com/2025/04/23/w...

Lipoprotein(a) This JAMA Insights discusses lipoprotein(a), including factors associated with elevated lipoprotein(a) levels, how to manage them, and atherosclerotic cardiovascular disease risk.

High lipoprotein(a) levels, defined as 50 mg/dL or greater, are associated with increased rates of atherosclerotic cardiovascular disease events and all-cause mortality. This JAMA Insights discusses lipoprotein(a).

#MedSky https://ja.ma/42Ma9Wv

Exciting News!

🚨 Save the Date for the 2026 Canadian Stroke Congress

🗻 Banff, Alberta

📅 May 23-26, 2026

More details coming soon at www.CanadianStroke.ca

#CSC2026 #StrokeCongress26 #SavetheDate #StrokeRecovery #StrokeResearch

Blood Pressure Lowering and Risk of Ischemic Lesions After Intracerebral Hemorrhage This multicenter, randomized clinical trial examines whether systolic blood pressure reduction increases the incidence of lesions detected with diffusion-weighted imaging in adult patients with acute ...

The ICH-ADAPT2 trial results were just published in
@jama.com Neurology. DWI lesions are observed in ~33% of patients with acute ICH. Our findings do not support a causal relationship between intensive BP lowering and DWI lesions in these patients.
jamanetwork.com/journals/jam...

This achievement would not have been possible without the commitment and expertise of our exceptional network of collaborators across 700+ sites in 38 countries. Thank you for your unwavering dedication and partnership!

We look forward to sharing the results once follow-up is complete — stay tuned!

Thrilled to share that the OCEANIC-STROKE trial (NCT05686070) led by PHRI & Bayer AG, has successfully completed enrolment of over 12,300 participants with non-cardioembolic ischemic #stroke over a recruitment period of only 26-months!

🔗https://phri.ca/oceanicstroke/

YouTube video by Medscape Staying Ahead in Stroke Prevention: The Rise of New Anticoagulation Approaches

For those interested and who were unable to join us at @americanheart.bsky.social #ISC2025 please find the recording of our @medscape.com webinar on the rise of new anticoagulants for stroke prevention here:
www.youtube.com/watch?v=D8f0...
@macdeptmed.bsky.social

Absolutely honoured to be delivering the inaugural Ralph Sacco Distinguished Lecture at the @universityofmiami.bsky.social 58th Neurology Update & Stroke Intensive Review. Huge thanks to Drs. Negar Asdaghi & Jose Romano for their generous invitation and gracious hospitality!
@macdeptmed.bsky.social

Congrats to Ken Butcher on successfully leading the ICH-ADAPT 2 RCT. Our results do not support the notion that BP lowering contributes to the majority of acute/subacute DWI lesions in patients with ICH. Alternative mechanisms need to be explored. #ISC2025
@ahascience.bsky.social

YouTube video by CMEPlanet CME at ISC 2025 - Best Practices for Managing Intracerebral Hemorrhage

For those who were unable to attend our update on best practices for managing ICH at #ISC2025, you can find the recording below:
www.youtube.com/watch?v=PiCn...

@christoslazaridis.bsky.social

ISC 2025

AHA/ASA Journals are on the ground at #ISC25

Check out the latest at www.ahajournals.org/isc

Should patients with #stroke and device-detected subclinical #AFib (SCAF) be treated with OAC?

Our subgroup analyses of the ARTESIA RCT (@thelancet.bsky.social) provide novel insights indicating that OAC is beneficial in appropriately selected patients.

www.thelancet.com/journals/lan...

WSO (@worldstrokeorg.bsky.social) Global ICH Factsheet
journals.sagepub.com/doi/full/10....

Combination Antithrombotic Therapy for Reduction of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease | Stroke BACKGROUND: Stroke secondary to intracranial atherosclerotic disease (ICAD) is associated with high recurrence risk despite currently available secondary prevention strategies. In patients with system...

Congratulation to Dr. Sashi Perera on leading this important phase II RCT suggesting reduced rates of ischemic cerebrovascular events with dual pathway inhibition (rivaroxaban+ASA) in patients with ICAD.

www.ahajournals.org/doi/10.1161/...
@macdeptmed.bsky.social @ahascience.bsky.social

Thrilled to announce that the #EnrichAF randomized trial completed enrolment of 948 patients in Q4 2024.

So grateful for the efforts of our global colleagues on reaching this milestone, who persevered despite many challenges along the way.

Follow-up is due to complete in Q1 2026. Stay tuned!

See our recent @worldstrokeorg.bsky.social scientific statement on secondary #stroke prevention in patients w #Afib. Big thanks Dr. Luciano Sposato for taking on the lion's share of work for this important piece.

@macdeptmed.bsky.social

journals.sagepub.com/doi/10.1177/...

🎉 Exciting News! 🎉

We are thrilled to announce that Dr. Deborah Siegal has been appointed as the next Co-Director of CanVECTOR (joining Co-Director Dr. Grégoire Le Gal), starting April 1, 2025!

Learn more: 🔗

buff.ly/4gHeS1a

#Research #Thrombosis #VTE

Kudos to Dr. Lauren Mai from @westernu.bsky.social
on leading this insightful narrative review outlining the protracted recovery trajectory of patients with ICH.

www.ahajournals.org/doi/10.1161/...

@macdeptmed.bsky.social @harvardmed.bsky.social @ahajournals.bsky.social @ahascience.bsky.social